{"result": "(\"entity\"<|>FEN/TPM<|>ORGANIZATION<|>FEN/TPM is a combination of drugs that is considered the most effective for weight loss based on clinical trial results.)\n##\n(\"entity\"<|>ORLISTAT<|>ORGANIZATION<|>Orlistat is a drug used for weight loss that has the least effect on body weight compared to other medications discussed.)\n##\n(\"entity\"<|>CETILISTAT<|>ORGANIZATION<|>Cetilistat is a gastric and pancreatic lipase inhibitor approved in Japan, similar to Orlistat but with fewer side effects.)\n##\n(\"entity\"<|>TESOFENSINA<|>ORGANIZATION<|>Tesofensina is a drug used for treating Parkinson's disease that has shown weight loss effects in a phase II trial.)\n##\n(\"entity\"<|>BELORANIF<|>ORGANIZATION<|>Beloranif is a drug that inhibits MetAP2, promoting fat oxidation and reducing appetite, showing significant weight loss in clinical trials.)\n##\n(\"entity\"<|>BUPROPION-ZONISAMIDA<|>ORGANIZATION<|>Bupropion-zonisamida is a drug combination being tested for enhanced weight loss effects with fewer side effects.)\n##\n(\"entity\"<|>FENTERMINA-LORCASERINA<|>ORGANIZATION<|>Fentermina-lorcaserina is another drug combination being explored for weight loss treatment.)\n##\n(\"entity\"<|>GLP1<|>ORGANIZATION<|>GLP1 refers to glucagon-like peptide-1, a hormone involved in appetite regulation, being studied in dual or triagonist combinations for obesity treatment.)\n##\n(\"entity\"<|>AMERICAN COLLEGE OF CARDIOLOGY<|>ORGANIZATION<|>The American College of Cardiology is a professional organization that provides guidelines for managing obesity and overweight in adults.)\n##\n(\"entity\"<|>OBESITY SOCIETY<|>ORGANIZATION<|>The Obesity Society is an organization focused on the study and treatment of obesity.)\n##\n(\"relationship\"<|>FEN/TPM<|>CETILISTAT<|>Both FEN/TPM and Cetilistat are discussed as effective treatments for obesity, indicating a relationship in their therapeutic use.<|>5)\n##\n(\"relationship\"<|>FEN/TPM<|>ORLISTAT<|>FEN/TPM is noted as more effective than Orlistat for weight loss, establishing a comparative relationship.<|>7)\n##\n(\"relationship\"<|>CETILISTAT<|>ORLISTAT<|>Cetilistat is similar to Orlistat but with fewer side effects, indicating a relationship based on their pharmacological properties.<|>6)\n##\n(\"relationship\"<|>TESOFENSINA<|>BELORANIF<|>Both drugs are mentioned in the context of obesity treatment, suggesting a relationship in their therapeutic applications.<|>4)\n##\n(\"relationship\"<|>BUPROPION-ZONISAMIDA<|>FENTERMINA-LORCASERINA<|>Both combinations are being tested for their effectiveness in treating obesity, indicating a relationship in their research focus.<|>5)\n##\n(\"relationship\"<|>GLP1<|>BUPROPION-ZONISAMIDA<|>GLP1 is being studied in combination with Bupropion-zonisamida for obesity treatment, establishing a direct relationship.<|>6)\n##\n(\"relationship\"<|>GLP1<|>FENTERMINA-LORCASERINA<|>GLP1 is also being explored in combination with Fentermina-lorcaserina, indicating a relationship in their use for obesity treatment.<|>6)\n##\n(\"relationship\"<|>AMERICAN COLLEGE OF CARDIOLOGY<|>OBESITY SOCIETY<|>Both organizations provide guidelines and research on the management of obesity, indicating a collaborative relationship.<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: presencia de pancreatitis o colecistitis. Tampoco hay experiencia en adolescentes (< 18 años) o mayores de 75 años. Se debe emplear con precaución en casos con antecedentes de colelitiasis, pancreatitis, gastroparesia o ideación suicida.\n\nDe manera conjunta y atendiendo a los resultados principales de los ensayos clínicos de cada fármaco de los aquí comentados, podemos advertir que la asociación de FEN/TPM es la combinación más eficaz para perder peso, siendo orlistat el que menos efecto tiene sobre el peso corporal (figura 2).\n\n## 4. Futuro de los tratamientos para la obesidad\n\nAlgunos fármacos se han ensayado con éxito para el tratamiento de la obesidad, como cetilistat, un inhibidor de las lipasas gástrica y pancreática, similar al orlistat, pero con menos efectos secundarios y, por tanto, mejor tolerancia. Cetilistat solo está aprobado en Japón (Oblean®, Cetisum®)32.\n\nTesofensina es un inhibidor de la recaptación de noradrenalina, dopamina y serotonina, que se emplea como fármaco en el tratamiento del Parkinson, aunque a dosis elevadas. Un único ensayo en fase II publicado en 2008, demostró que la dosis de 0,5 mg durante 24 semanas produjo una disminución del 9% del peso corporal, mayor que placebo, con escasa pérdida de seguimiento de pacientes (21%); sin embargo, su desarrollo clínico se ha quedado estancado. Los efectos secundarios más importantes son los derivados de su acción central: sequedad de mucosas, estreñimiento, insomnio, intranquilidad33.\n\nBeloranif es un fármaco inhibidor de la metionina aminopeptidasa-2 (MetAP2), que reduce la biosíntesis de grasa, favorece su oxidación y la lipólisis. El tratamiento con este fármaco presenta el efecto dual de incrementar el metabolismo graso y reducir la sensación de apetito. En estudios clínicos en fase II, beloranif produjo una pérdida de peso entre 7-10% superior a placebo34; pero, el fallecimiento inesperado de un paciente en un ensayo fase III, ha paralizado el desarrollo del fármaco.\n\nEl tratamiento farmacológico de la obesidad en los próximos años tendrá un mayor protagonismo en la combinación de moléculas con diferentes mecanismos de acción para potenciar sus efectos con los menores efectos secundarios. Se están ensayando asociaciones de fármacos conocidos como bupropión-zonisamida o de fentermina-lorcaserina. Pero, son los agonistas duales o triagonistas de hormonas gastrointestinales (GLP1 junto a análogos de glucagón, oxintomodulina o GIP), los que están ocupando las primeras líneas de investi-\n---\nTema 8. Tratamiento farmacológico de la obesidad 139\n\n| Fármaco | Dosis | F-II/SCALE | COR-I/II/BMOD | SCALE-DM | COR-DM | BLOOM-BLOSSOM | BLOOM-DM | Metanálisis |\n|---------|-------|------------|---------------|----------|--------|----------------|-----------|-------------|\n| Fent/Topir | 15/92 mg | 8.9 | | | | | | |\n| | 7.5/45 mg | 6.6 | | | | | | |\n| LIRA 3 mg | | 5.9 | | 4.0 | | | | |\n| BN 360/32 mg | | | 4.7 | | 3.3 | | | |\n| Lorcaserina | | | | | | 3.3 | 3.1 | |\n| Orlistat | | | | | | | | 2.9 |\n\nFigura 2. Eficacia en la pérdida de peso a un año según diferentes fármacos comercializados: diferencia con placebo (análisis por intención de tratar).\n\ngación más sólidas35-38. Estos nuevos fármacos tendrán que superar los efectos secundarios a nivel central y de riesgo cardiovascular que han hecho fracasar en el pasado a otros que les precedieron.\n\n## 5. Bibliografía\n\n1. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014; 63(25 Pt B): 2985-3023.\n\n2. Middleton KM, Patidar SM, Perri MG. The impact of extended care on the long-term maintenance of weight loss: a systematic review and meta-analysis. Obesity Rev. 2012; 13: 509-17.\n\n3. Krentz AJ, Fujioka K,Hompesch M. Evolution of pharmacological obesity treatments: focus\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}